Incyte Supports Those Affected by Rare Blood Cancers on MPN Awareness Day and Throughout Blood Cancer Awareness Month
September 08 2016 - 9:00AM
Business Wire
MPN Landmark Survey Underscores Burden of
Disease in MPN Patients and the Importance of Raising Awareness
Today and Throughout the Month of September
Incyte Corporation calls for increased awareness and support for
those living with myeloproliferative neoplasms (MPNs) today, MPN
Awareness Day, and throughout September, Blood Cancer Awareness
Month. MPNs are a closely related group of rare, progressive blood
cancers, and occur when the bone marrow cells that produce the
body’s blood cells develop and function abnormally. The three main
MPNs, myelofibrosis (MF), polycythemia vera (PV) and essential
thrombocythemia (ET), are estimated to affect 200,000 individuals
in the U.S. Of these, PV is the most prevalent.
Findings from the Incyte funded MPN Landmark Survey, a
large-scale, extensive analysis of over 800 MPN patients published
in BMC Cancer, underscore the burden of disease among MPN patients
and the need for continued awareness. Patients who participated in
the survey reported that MPN-related symptoms reduced their quality
of life (MF, 81%; PV, 66%; ET, 57%). Additionally, the MPN Landmark
Survey revealed the following:
- MPN patients surveyed reported that
their disease had affected their family or social life(MF, 79%; PV,
63%; ET, 55%)
- MPN patients surveyed reported that
they have had to cancel planned activities because of their disease
(MF, 41%; PV, 30%; ET, 27%)
- MPN patients surveyed reported having
to call in sick to work at least once in the preceding 30 days (MF,
29%; PV, 19%; ET, 22%)
The MPN Landmark Survey also found that patients ultimately
diagnosed with MPNs faced a long road to diagnosis, with many
respondents reporting that they experienced at least one
MPN-related symptom for one year or more before diagnosis (MF, 49%;
PV, 61%; ET, 58%). To read the published MPN Landmark Survey
findings, click here; additional MPN Landmark Survey findings are
expected to be published later this year.
“The MPN Landmark Survey results highlight the significant
challenges patients with MPNs face on a daily basis and strongly
reinforce the need for increased awareness and understanding of
MPNs,” said Hervé Hoppenot, Incyte’s Chief Executive Officer. “On
this fourth annual MPN Awareness Day, and every day, we remain
committed to supporting the MPN community by helping to raise
awareness of MPNs and improving care for patients suffering from
these rare and debilitating blood cancers.”
To support people impacted by MPNs, Incyte will be hosting an
“Ask an MPN Expert” Facebook Live Chat today at 6 PM
Eastern where an MPN expert will be on hand to answer questions in
real time from patients and caregivers about MPNs and the MPN
Landmark Survey. To participate in the live chat, visit the “Voices
of MPN” Facebook page.
Additionally, on MPN Awareness Day and throughout the month of
September, MPN patients, physicians and caregivers are encouraged
to share their stories, show their support and help raise awareness
of these rare disorders through a variety of activities,
including:
- MPN Awareness Social Media Photo
Filter: Show your support and raise awareness of MPNs by
visiting http://mpnawareness.twibbon.com/ and adding an MPN
Awareness photo filter to your Facebook or Twitter profile
picture.
- #Connect4MPNs: Use this hashtag
on social media today and throughout the month of September to
share your personal experiences and raise awareness for MPNs.
- Voices of MPN: Visit
www.voicesofmpn.com to access helpful resources about living with
MPNs, including the “Raise Your Voice” toolkit, which features tips
on how to get involved and spread awareness of MPNs.
“MPN Awareness Day is an important time for the community to
unite and inspire change by bringing to the forefront MPNs and the
challenges patients and their loved ones face on a daily basis,”
said Susan Melvin Hill, 2015 MPN Hero Award Recipient. “I am
motivated by the members of the MPN community who have the strength
to share their stories and educate the broader population about the
needs of MPN patients across the U.S.”
Stay connected and informed about all of the MPN awareness
activities happening throughout September by “Liking” the “Voices
of MPN” Facebook page, following “Voices of MPN” on Pinterest or
using the hashtag #Connect4MPNs.
About Myeloproliferative Neoplasms (MPNs)
Myeloproliferative neoplasms (MPNs) are a closely related group
of blood cancers in which the bone marrow cells that produce the
body’s blood cells develop and function abnormally.1 The three main
myeloproliferative neoplasms are myelofibrosis (MF), polycythemia
vera (PV) and essential thrombocythemia (ET).1 MPNs are progressive
blood cancers that can strike anyone at any age, but they are more
common in older adults. Estimates of the prevalence of MPNs vary,
but analysis of claims data suggests there may be as many as
200,000 people in the U.S. living with MF, PV or ET.2
About Incyte
Incyte Corporation is a Wilmington, Delaware-based
biopharmaceutical company focused on the discovery, development and
commercialization of proprietary therapeutics. For additional
information on Incyte, please visit the Company’s website at
www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
© 2016, Incyte Corporation. All rights
reserved. INC-1180 09/16
References
1 Understanding MPNs. MPN Research Foundation.
http://www.mpnresearchfoundation.org/overview-page2 Data on
File.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160908005415/en/
Incyte CorporationMediaCatalina Loveman,
302-498-6171cloveman@incyte.comorElliot Fox,
212-257-6724efox@w2ogroup.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Apr 2023 to Apr 2024